Lucid Diagnostics financials
$0.8090+0.41%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.3M | $1.5M | $1.2M | $1.2M | $828.0K | $1.2M | $1.2M | $976.0K | $1.0M | $1.0M | $783.0K |
| Gross profit | $29.0K | -$369.0K | -$356.0K | -$486.0K | -$400.0K | -$723.0K | -$948.0K | -$512.0K | -$638.0K | -$655.0K | -$417.0K | -$851.0K |
| Gross margin | 2.0% | −29.4% | −23.7% | −40.1% | −34.4% | −87.3% | −79.2% | −43.7% | −65.4% | −65.4% | −40.1% | −108.7% |
| Operating income | -$12.8M | -$12.1M | -$14.0M | -$11.8M | -$11.4M | -$12.5M | -$12.4M | -$11.7M | -$11.2M | -$10.8M | -$11.5M | -$11.1M |
| Net income | -$14.7M | -$23.6M | -$16.3M | -$10.4M | -$7.9M | -$36.0M | -$11.5M | -$12.4M | -$11.0M | -$18.1M | -$10.8M | -$14.2M |
| Net margin | −998.3% | −1881.2% | −1081.5% | −858.5% | −678.2% | −4350.0% | −964.2% | −1055.5% | −1127.6% | −1809.0% | −1041.3% | −1814.6% |
| Diluted EPS | $-0.08 | $-0.17 | $-0.12 | $-0.10 | $-0.08 | $-0.52 | $-0.20 | $-0.25 | $-0.23 | $-0.40 | $-0.26 | $-0.34 |
| EBITDA | -$12.6M | -$11.9M | -$14.0M | -$11.3M | -$11.2M | -$12.3M | -$12.4M | -$11.2M | -$11.0M | -$10.3M | -$10.8M | -$10.5M |
| Operating cash flow | -$11.3M | -$12.1M | -$12.6M | -$10.9M | -$10.5M | -$12.5M | -$9.9M | -$10.2M | -$11.5M | -$12.6M | -$10.0M | -$8.8M |
| Free cash flow | -$11.3M | -$12.3M | -$12.6M | -$10.9M | -$10.6M | -$12.6M | -$10.1M | -$10.2M | -$11.5M | -$12.6M | -$10.2M | -$8.8M |
| Diluted shares | 183.1M | 140.1M | 131.8M | 108.2M | 99.0M | 68.8M | 58.5M | 50.4M | 48.2M | 45.0M | 42.4M | 41.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.4M | $27.9M | $34.7M | $47.3M | $31.1M | $25.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $23.5M | $25.2M | $24.0M | $22.3M | $25.3M | $32.8M |
| Total assets | $38.9M | $34.1M | $40.4M | $53.2M | $38.7M | $32.8M |
| Total liabilities | $28.0M | $30.1M | $29.5M | $27.4M | $30.8M | $38.2M |
| Shareholders' equity | $10.9M | $4.0M | $10.9M | $25.8M | $7.9M | -$5.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology